Trial Outcomes & Findings for Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes (NCT NCT01691079)
NCT ID: NCT01691079
Last Updated: 2020-06-05
Results Overview
COMPLETED
PHASE4
20 participants
The outcome measures will be assessed over an expected average of 6 months.
2020-06-05
Participant Flow
PI left institution and sincere efforts were made to contact the PI, but were unsuccessful. No data are available to report.
Participant milestones
| Measure |
Placebo
placebo 2 puffs prior to exercise challenge
Placebo: Inhaled placebo administered before exercise.
|
Ipratropium Bromide
ipratropium bromide HFA 2 puffs prior to exercise challenge
ipratropium bromide: Inhaled ipratropium bromide administered before exercise.
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: The outcome measures will be assessed over an expected average of 6 months.Population: PI left institution and sincere efforts were made to contact the PI, but were unsuccessful. No data are available to report.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: The outcome measures will be assessed over an expected average of 6 months.Population: PI left institution and sincere efforts were made to contact the PI, but were unsuccessful. No data are available to report.
Outcome measures
Outcome data not reported
Adverse Events
Placebo
Ipratropium Bromide
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place